Jordan Berlin, MD
Enriched profileProfessor of Medicine (Cornelius Abernathy Craig Chair; Ingram Professor of Cancer Research), Director, Division of Hematology and Oncology · Vanderbilt University Medical Center
Jordan Berlin is Professor of Medicine (Cornelius Abernathy Craig Chair; Ingram Professor of Cancer Research), Director, Division of Hematology and Oncology at Vanderbilt University Medical Center. OpenAlex indexes 650 publications with 40,633 citations (h-index 76); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Jordan Berlin, MD, is Professor of Medicine (Cornelius Abernathy Craig Chair at Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center. The public record shows 650 publications with 40,633 citations (h-index 76), centered on Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 17 companies, 8 NIH-funded awards (2003–2024).
- Most recent indexed publication: 2025 · The oncologist
- Top research focus: Colorectal Cancer Treatments and Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 249.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- IKS04 Regimen in Advanced Solid Tumors That Express CA242
Sponsor: Iksuda Therapeutics Ltd.
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Sponsor: Nested Therapeutics, Inc
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Healthcare KGaAProgram year20254 payments$16,004openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20252 payments
- Ipsen Biopharmaceuticals, IncProgram year20254 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.2%Kinase inhibitor52.2%Sutent100%Part D<11 patientsMetabolism & gastrointestinal
47.8%Antidiarrheal microorganisms47.8%Zenpep100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
8 NIH research awards on record, funded 2003–2024 per NIH RePORTER. The latest:
- Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC
Vanderbilt University Medical Center
FY2024$142,081P50CA236733 - Project 2: Targeting Glutamine Metabolism to Enhance EGFR Blockade in Wild-Type RAS CRC
Vanderbilt University Medical Center
FY2023$399,535P50CA236733 - Vanderbilt Network Lead Academic Participating Site for the NCTN
Vanderbilt University Medical Center
FY2022$507,576UG1CA233270
Congress activity
Updated 27 Aug 2026
156 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Access to fertility preservation services among commercially insured adults with early-onset colorectal cancer.
ASCO Annual Meeting
ASCO2026Co-author - Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.
Clinical cancer research
Clinical Trial2025 - Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.
Clinical cancer research
Clinical Trial2025 - Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights.
JCO oncology practice
Article2025 - Management of Locally Advanced Rectal Cancer: ASCO Guideline.
Journal of clinical oncology
Guideline2024
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jordan-berlin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/VanderbiltIngram/videos/dr-jordan-berlins-groundbreaking-work-at-vanderbilt-ingram-cancer-center-is-tran/1280228806623779
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/vumc_cancer/reel/DDKfA6wtsxJ
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Editorial & leadership roles
journal and society appointments- Chair
ECOG-ACRIN Gastrointestinal Cancer Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ecog-acrin.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog-ecog-acrin.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →blog-ecog-acrin.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Director for Clinical Research
Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Co-Leader
Gastrointestinal Cancer Research Program, Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Director
Phase I Program, Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.org ↗
- OnLive contributor/interviewee
recurring video/text interviews on GI and pancreatic cancer topics
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
Brian Rini, MD
Vanderbilt University Medical Center
William Schaffner, MD
Vanderbilt University Medical Center
Julia Lewis, MD
Vanderbilt University Medical Center